Trial · NCT01018563
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Ovarian Tumor Marker (Cancer Antigen 125 [CA125]) Response | Farletuzumab 62.5 mg/m^2 | Participant 1 (dose group: 62.5 mg/m^2)-C | 77.2 | months | |
| Duration of Ovarian Tumor Marker (Cancer Antigen 125 [CA125]) Response | Farletuzumab 62.5 mg/m^2 | Participant 2 (dose group: 62.5 mg/m^2)-C | 73.3 | months | |
| Duration of Ovarian Tumor Marker (Cancer Antigen 125 [CA125]) Response | Farletuzumab 100 mg/m^2 | Participant 3 (dose group: 100 mg/m^2) | 18.0 | months | |
| Progression-Free Survival (PFS) by GCIG | Farletuzumab 62.5 mg/m^2 | Participant 1 (dose group: 62.5 mg/m^2)-C: GCIG | 77.8 | months | |
| Progression-Free Survival (PFS) by GCIG | Farletuzumab 62.5 mg/m^2 | Participant 2 (dose group: 62.5 mg/m^2)-C: GCIG | 75.8 | months | |
| Progression-Free Survival (PFS) by GCIG | Farletuzumab 100 mg/m^2 | Participant 3 (dose group: 100 mg/m^2): GCIG | 25.1 | months | |
| Overall Survival (OS) | Farletuzumab 62.5 mg/m^2 | Participant 1 (dose group: 62.5 mg/m^2)-C | 78.3 | months | |
| Overall Survival (OS) | Farletuzumab 62.5 mg/m^2 | Participant 2 (dose group: 62.5 mg/m^2)-C | 76.7 | months | |
| Overall Survival (OS) | Farletuzumab 100 mg/m^2 | Participant 3 (dose group: 100 mg/m^2) | 59.5 | months | |
| Duration of Second Remission | Farletuzumab 62.5 mg/m^2 | Participant 1 (dose group: 62.5 mg/m^2) | 41.0 | months | |
| Duration of Second Remission | Farletuzumab 62.5 mg/m^2 | Participant 2 (dose group: 62.5 mg/m^2)-C | 74.2 | months | |
| Duration of Second Remission | Farletuzumab 100 mg/m^2 | Participant 3 (dose group: 100 mg/m^2) | 29.5 | months | |
| Duration of Third Remission | Farletuzumab 62.5 mg/m^2 | 37.3 | months | ||
| Duration of Third Remission | Farletuzumab 100 mg/m^2 | 25.0 | months | ||
| Number of Participants With Best Overall Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.0 Criteria | Farletuzumab 62.5 mg/m^2 | CR | 1 | Participants | |
| Number of Participants With Best Overall Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.0 Criteria | Farletuzumab 100 mg/m^2 | CR | 1 | Participants | |
| Number of Participants With Best Overall Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.0 Criteria | Farletuzumab 62.5 mg/m^2 | SD | 1 | Participants | |
| Number of Participants With Best Overall Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.0 Criteria | Farletuzumab 100 mg/m^2 | SD | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01018563/results